الفهرس 
Liver and Hepatitis C virus (HCV)Only 14 pages are availabe for public view
 |  | from | 173 |  |  |
| | | from | 173 | | |
Abstract
Summary
The World Health Organization has declared HCV a global health problem, with approximately 3% of the world’s population (roughly 170-200 million people) infected with HCV with considerable regional variations. In Egypt the situation is quite worse; the overall prevalence (percentage of people) positive for antibody to HCV was 14.7%. Egypt contains the highest prevalence of hepatitis C in the world. Interestingly, genotype 4 represents over 90% of cases in Egypt.
The combination treatment of two direct acting antiviral drugs, Ombitasvir, Paritaprevir with low dose of ritonavir (Qurevo) plus ribavirin is preferred for patients with HCV genotype 4 infections because it has high response near to100% in some studies, in addition to it has low side effects .
The aim of this work is to evaluate the response to treatment of chronic HCV genotype 4 using QUREVO with ribavirin for 12 weeks duration.
In order to achieve that, 207 chronic HCV patients who had been treated by combination therapy (QUREVO and RIBAVIRIN) were enrolled.
A written consent were taken from all patients, medical history taking, clinical examination, pre-treatment laboratory evaluation and abdominal ultrasound. Follow up of all patients with CBC, liver function test, kidney function test and HCV PCR quantitative after 12 weeks of starting treatment and 3 months after the end of treatment was done.
In this study a significant correlation between response to combination regimen and some clinical, laboratory and imaging data was found.
Pre-treatment Aspartate amino transaminase AST and Alanine transaminase ALT were significantly reduced from baseline to 4-weeks of treatment and after 8 weeks of treatment. There was also a statistically significant improvement in liver fibrosis following treatment.
There was evaluation in albumin that detects improvement in liver functions.
Results also showed that the SVR rate at the end of treatment with QUREVO was 95% while SVR12 rate 3 months after the end of treatment with QUREVO was 94.5%.